Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984130669> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2984130669 endingPage "77" @default.
- W2984130669 startingPage "69" @default.
- W2984130669 abstract "Background: Regarding the leukocytes infiltration into the synovium of Rheumatoid Arthritis (RA) patients is mostly mediated by chemokine ligands and receptors, and following the efficient and motivating results of international Phase III clinical trial of β-D-Mannuronic acid (M2000) patented EP067919 (2017), as a novel anti-inflammatory drug, in patients with RA, the present research was designed. Objectives: This study aimed to assess the oral administration effects of this new drug on gene expression of some chemokine receptors and ligands, including CXCR4, CXCR3, CCR2, CCR5 and CCL2/MCP-1 in PBMCs of patients with active form of RA. Methods: Twelve patients suffering from RA, with inadequate response to conventional drugs were selected (Clinical trial identifier IRCT2017100213739N10) and 1000mg/day of M2000 was orally administrated to them for 12 weeks. The mRNA expression of target molecules was then evaluated in PBMCs of the patients before and after treatment with M2000 using real-time PCR and was compared to healthy controls. Patents related to this study were also reviewed. Results: The results showed that M2000 was able to significantly down-regulate the mRNA expression of CXCR4, CCR2 and CCL2/MCP-1 in the PBMCs of the RA patients. It should be noted that the gene expression situation of the target molecules was in coordinate with the clinical and paraclinical assessments in the patients. Conclusion: Taken together, the results of this investigation revealed the part of molecular and immunological mechanisms of drug Mannuronic acid (M2000) in the treatment of RA, based on chemokine ligands and receptors mediated processes." @default.
- W2984130669 created "2019-11-22" @default.
- W2984130669 creator A5050438097 @default.
- W2984130669 creator A5052050053 @default.
- W2984130669 creator A5052284047 @default.
- W2984130669 creator A5059198125 @default.
- W2984130669 creator A5069199978 @default.
- W2984130669 creator A5072848668 @default.
- W2984130669 creator A5076369814 @default.
- W2984130669 date "2020-03-30" @default.
- W2984130669 modified "2023-10-16" @default.
- W2984130669 title "The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients" @default.
- W2984130669 doi "https://doi.org/10.2174/1872213x13666191114111822" @default.
- W2984130669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7509734" @default.
- W2984130669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31729947" @default.
- W2984130669 hasPublicationYear "2020" @default.
- W2984130669 type Work @default.
- W2984130669 sameAs 2984130669 @default.
- W2984130669 citedByCount "5" @default.
- W2984130669 countsByYear W29841306692021 @default.
- W2984130669 countsByYear W29841306692022 @default.
- W2984130669 crossrefType "journal-article" @default.
- W2984130669 hasAuthorship W2984130669A5050438097 @default.
- W2984130669 hasAuthorship W2984130669A5052050053 @default.
- W2984130669 hasAuthorship W2984130669A5052284047 @default.
- W2984130669 hasAuthorship W2984130669A5059198125 @default.
- W2984130669 hasAuthorship W2984130669A5069199978 @default.
- W2984130669 hasAuthorship W2984130669A5072848668 @default.
- W2984130669 hasAuthorship W2984130669A5076369814 @default.
- W2984130669 hasBestOaLocation W29841306692 @default.
- W2984130669 hasConcept C101666144 @default.
- W2984130669 hasConcept C126322002 @default.
- W2984130669 hasConcept C12823836 @default.
- W2984130669 hasConcept C129470790 @default.
- W2984130669 hasConcept C13373296 @default.
- W2984130669 hasConcept C170493617 @default.
- W2984130669 hasConcept C17502307 @default.
- W2984130669 hasConcept C203014093 @default.
- W2984130669 hasConcept C206615009 @default.
- W2984130669 hasConcept C25532541 @default.
- W2984130669 hasConcept C2777575956 @default.
- W2984130669 hasConcept C71924100 @default.
- W2984130669 hasConcept C98274493 @default.
- W2984130669 hasConceptScore W2984130669C101666144 @default.
- W2984130669 hasConceptScore W2984130669C126322002 @default.
- W2984130669 hasConceptScore W2984130669C12823836 @default.
- W2984130669 hasConceptScore W2984130669C129470790 @default.
- W2984130669 hasConceptScore W2984130669C13373296 @default.
- W2984130669 hasConceptScore W2984130669C170493617 @default.
- W2984130669 hasConceptScore W2984130669C17502307 @default.
- W2984130669 hasConceptScore W2984130669C203014093 @default.
- W2984130669 hasConceptScore W2984130669C206615009 @default.
- W2984130669 hasConceptScore W2984130669C25532541 @default.
- W2984130669 hasConceptScore W2984130669C2777575956 @default.
- W2984130669 hasConceptScore W2984130669C71924100 @default.
- W2984130669 hasConceptScore W2984130669C98274493 @default.
- W2984130669 hasIssue "1" @default.
- W2984130669 hasLocation W29841306691 @default.
- W2984130669 hasLocation W29841306692 @default.
- W2984130669 hasOpenAccess W2984130669 @default.
- W2984130669 hasPrimaryLocation W29841306691 @default.
- W2984130669 hasRelatedWork W1982916524 @default.
- W2984130669 hasRelatedWork W2059355709 @default.
- W2984130669 hasRelatedWork W2094862143 @default.
- W2984130669 hasRelatedWork W2169632765 @default.
- W2984130669 hasRelatedWork W2170611844 @default.
- W2984130669 hasRelatedWork W2589564301 @default.
- W2984130669 hasRelatedWork W2606755686 @default.
- W2984130669 hasRelatedWork W2948755509 @default.
- W2984130669 hasRelatedWork W2984130669 @default.
- W2984130669 hasRelatedWork W3032379494 @default.
- W2984130669 hasVolume "14" @default.
- W2984130669 isParatext "false" @default.
- W2984130669 isRetracted "false" @default.
- W2984130669 magId "2984130669" @default.
- W2984130669 workType "article" @default.